2.62
price up icon30.35%   0.61
 
loading
I Mab Adr stock is traded at $2.62, with a volume of 44.45M. It is up +30.35% in the last 24 hours and up +11.97% over the past month. I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
See More
Previous Close:
$2.01
Open:
$2.26
24h Volume:
44.45M
Relative Volume:
36.35
Market Cap:
$213.53M
Revenue:
$3.91M
Net Income/Loss:
$-206.53M
P/E Ratio:
-1.0554
EPS:
-2.4825
Net Cash Flow:
$-167.78M
1W Performance:
+24.17%
1M Performance:
+11.97%
6M Performance:
+156.86%
1Y Performance:
+100.00%
1-Day Range:
Value
$2.25
$3.44
1-Week Range:
Value
$1.65
$3.44
52-Week Range:
Value
$0.595
$3.44

I Mab Adr Stock (IMAB) Company Profile

Name
Name
I Mab Adr
Name
Phone
-
Name
Address
-
Name
Employee
32
Name
Twitter
Name
Next Earnings Date
2025-03-31
Name
Latest SEC Filings
Name
IMAB's Discussions on Twitter

Compare IMAB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IMAB
I Mab Adr
2.62 164.14M 3.91M -206.53M -167.78M -2.4825
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
462.13 117.32B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.87 58.89B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
401.80 51.14B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
673.80 41.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.01 32.59B 3.81B -644.79M -669.77M -6.24

I Mab Adr Stock (IMAB) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-09-21 Initiated Siebert Williams Shank Buy
Jun-02-21 Initiated Daiwa Securities Buy
Mar-15-21 Initiated Needham Buy
Mar-03-21 Reiterated H.C. Wainwright Buy
Feb-25-21 Initiated Piper Sandler Overweight
Dec-07-20 Initiated H.C. Wainwright Buy
Jul-27-20 Initiated Cantor Fitzgerald Overweight
Feb-12-20 Initiated China Renaissance Buy
Feb-11-20 Initiated Jefferies Buy
View All

I Mab Adr Stock (IMAB) Latest News

pulisher
Aug 01, 2025

I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares - GlobeNewswire Inc.

Aug 01, 2025
pulisher
Jul 29, 2025

I-Mab ADR (IMAB) Stock: Navigating a Year of Stock Volatility - investchronicle.com

Jul 29, 2025
pulisher
Jul 17, 2025

I-Mab acquires Bridge Health to strengthen givastomig development By Investing.com - Investing.com South Africa

Jul 17, 2025
pulisher
Jul 17, 2025

I-Mab acquires Bridge Health to strengthen givastomig development - Investing.com India

Jul 17, 2025
pulisher
Jul 16, 2025

Best Income Stocks to Buy for July 16th - The Globe and Mail

Jul 16, 2025
pulisher
Jul 11, 2025

I-MAB files 6-K to amend US$21M ADS shelf registration | BQ SEC FilingForm 6-K - Stock Titan

Jul 11, 2025
pulisher
Jul 02, 2025

I-Mab reports 83% response rate for givastomig in gastric cancer study - Investing.com India

Jul 02, 2025
pulisher
Jun 30, 2025

I-Mab’s givastomig shows promising results in gastric cancer study - Investing.com

Jun 30, 2025
pulisher
Jun 27, 2025

I-Mab stock maintains buy rating at H.C. Wainwright on strong cancer data - Investing.com

Jun 27, 2025
pulisher
Jun 26, 2025

I-Mab reports 71% response rate for gastric cancer drug in trial - Investing.com

Jun 26, 2025
pulisher
Jun 24, 2025

H.C. Wainwright reiterates buy rating on I-Mab stock ahead of key data By Investing.com - Investing.com South Africa

Jun 24, 2025
pulisher
Jun 24, 2025

H.C. Wainwright reiterates buy rating on I-Mab stock ahead of key data - Investing.com

Jun 24, 2025
pulisher
Jun 17, 2025

I-Mab at H.C. Wainwright: Strategic Shift Towards U.S. Operations - Investing.com

Jun 17, 2025
pulisher
Jun 17, 2025

I-Mab at H.C. Wainwright: Strategic Shift Towards U.S. Operations By Investing.com - Investing.com South Africa

Jun 17, 2025
pulisher
Jun 17, 2025

Market Momentum: Abpro Holdings Inc (ABP) Registers a 3.72 Increase, Closing at 0.22 - DWinneX

Jun 17, 2025
pulisher
Jun 17, 2025

Unity Software Inc’s Market Journey: Closing Strong at 24.40, Up 3.13 - DWinneX

Jun 17, 2025
pulisher
Jun 13, 2025

I-Mab Sponsored ADR (IMAB)'s Technical Outlook is Bright After Key Golden Cross - MSN

Jun 13, 2025
pulisher
Jun 12, 2025

I-Mab regains Nasdaq compliance as shares maintain $1 minimum bid - Investing.com India

Jun 12, 2025
pulisher
Jun 12, 2025

I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement - Yahoo Finance

Jun 12, 2025
pulisher
Jun 11, 2025

Figure 1. Protein and mRNA expressions of P-glycoprotein in BEL-7402... - researchgate.net

Jun 11, 2025
pulisher
Jun 11, 2025

Willdan Group, Inc.'s (NASDAQ:WLDN) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects? - Yahoo Finance

Jun 11, 2025
pulisher
Jun 11, 2025

Can This Unstoppable Stock Join Microsoft, Nvidia, Apple, Amazon, Alphabet, Meta Platforms, and Tesla in the $1 Trillion Club? - Yahoo Finance

Jun 11, 2025
pulisher
Jun 10, 2025

Graphjet Technology Discloses Notice from Nasdaq - Yahoo Finance

Jun 10, 2025
pulisher
Jun 07, 2025

B. Riley Financial granted extension from Nasdaq regarding listing rules - Yahoo Finance

Jun 07, 2025
pulisher
Jun 06, 2025

I-Mab Sponsored ADR (IMAB) is a Great Momentum Stock: Should You Buy? - sharewise

Jun 06, 2025
pulisher
Jun 06, 2025

All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy - Yahoo Finance

Jun 06, 2025
pulisher
Jun 05, 2025

Asian Stocks Shine As Biotech And Financials Lead Gains - Finimize

Jun 05, 2025
pulisher
Jun 05, 2025

Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success - Yahoo Finance

Jun 05, 2025
pulisher
Jun 03, 2025

I-Mab to Participate in the H.C. Wainwright “HCW@Home” Series - Yahoo Finance

Jun 03, 2025
pulisher
May 28, 2025

I-Mab stock surges on Lucid Capital’s buy rating initiation By Investing.com - Investing.com South Africa

May 28, 2025
pulisher
May 28, 2025

I-Mab stock surges on Lucid Capital’s buy rating initiation - Investing.com

May 28, 2025
pulisher
May 28, 2025

Lucid Capital sets I-Mab stock Buy rating, $5 target on cancer drug potential - Investing.com

May 28, 2025
pulisher
May 17, 2025

I-Mab’s Financial Report Highlights Givastomig Progress - TipRanks

May 17, 2025
pulisher
May 15, 2025

I-Mab Reports First Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance

May 15, 2025
pulisher
May 06, 2025

I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023 - Barchart.com

May 06, 2025
pulisher
May 05, 2025

I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC - Barchart.com

May 05, 2025
pulisher
Apr 14, 2025

After Plunging -20.33% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) - Yahoo Finance

Apr 14, 2025
pulisher
Apr 11, 2025

After Plunging -19.7% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) - Yahoo Finance

Apr 11, 2025
pulisher
Apr 07, 2025

I-Mab at Needham Conference: Strategic Transformation Unveiled - Investing.com

Apr 07, 2025
pulisher
Apr 07, 2025

I-Mab at Needham Conference: Strategic Transformation Unveiled By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 04, 2025

I-Mab’s Transformative Year: Financial and Strategic Highlights - TipRanks

Apr 04, 2025
pulisher
Apr 04, 2025

I-Mab stock price target lowered to $7 at H.C. Wainwright By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 04, 2025

I-Mab stock price target lowered to $7 at H.C. Wainwright - Investing.com India

Apr 04, 2025
pulisher
Apr 03, 2025

I-Mab stock touches 52-week low at $0.72 amid market challenges - Investing.com

Apr 03, 2025
pulisher
Mar 21, 2025

I-Mab faces Nasdaq delisting over bid price rule By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

I-Mab faces Nasdaq delisting over bid price rule - Investing.com

Mar 21, 2025
pulisher
Mar 07, 2025

I-Mab advances gastric cancer treatment with swift trial enrollment - Investing.com

Mar 07, 2025

I Mab Adr Stock (IMAB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.59
price up icon 0.93%
$37.11
price up icon 0.84%
$108.69
price up icon 1.31%
$27.07
price up icon 2.65%
$107.34
price down icon 0.15%
biotechnology ONC
$299.01
price down icon 0.70%
Cap:     |  Volume (24h):